This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
This fall, we come together for the largest and most innovative cardiometabolic event in honor of the legacy of Dr. George L. Practical, Future-Focused Education Cardiorenal and metabolic diseases, fueled by poor lifestyle choices and health conditions, lead to type 2 diabetes, cardiovascular disease, and chronic kidney disease.
The CAD Staging System is a noninvasive imaging-based investigational software device that analyzes important and actionable features of coronary atherosclerosis, stenosis and ischemia. Cleerly’s mission extends beyond innovation; it is a commitment to saving lives by revolutionizing the prevention and treatment of heart disease.
The Hilton Boston Park Plaza became a hub of innovation, education, and collaboration, uniting nearly 500 clinicians under a shared mission: to redefine cardiometabolic care. The 19th Annual CMHC was more than just CME/CE medical education—it ignited global collaboration and inspired groundbreaking innovations.
Adipose-derived mesenchymal stem cells (ASCs) represent an innovative candidate to treat ischemic heart disease (IHD) due to their abundance, renewable sources, minor invasiveness to obtain, and no ethical limitations. Exosomes from ASCs also play an indispensable role in this process.
This October, we gather for the largest and most innovative cardiometabolic event, honoring Dr. Bakris’ profound impact on our community. Aronne, MD Expert Perspectives on Initiating and Maintaining Insulin Therapy in Type 2 Diabetes Patients Jay H. When I heard of his passing, I felt quite sad.
February 1, 2024 — As cardiologists, heart disease patients and the organizations that serve them across the country embark on American Heart Month, DAIC has compiled a snapshot of significant cardiovascular disease (CVD) and stroke statistics, along with a review of the atherosclerosis drug market. million have diagnosed diabetes; and 9.7
Cardiometabolic risk encompasses a complex spectrum of interrelated conditions, including cardiovascular disease, type 2 diabetes, and metabolic syndrome. We need a comprehensive and innovative approach to cardiorenal metabolic management and risk reduction to address this challenge.
As the AHA celebrates its 100th year, the conference reflected on a century of innovation while exploring the future of cardiovascular disease prevention and management. The American Heart Association (AHA) Congress 2024 , held from November 1618, marked a pivotal moment in cardiovascular and metabolic health. Read the published study.
From breakthrough medications to innovative technologies, there is a lot for cardiometabolic clinicians professionals to celebrate. Eversense’s 365-day CGM and Medtronic’s Simplera Sync were among the major highlights, offering patients with diabetes more comfortable, longer-lasting monitoring options.
ObjectiveMitochondrial dysfunction is associated with increased risk of atherosclerosis by disrupting key cellular processes that contribute to premature vascular ageing. EOCAD patients had lower mtDNA-CN (p<0.001) and higher mtDNA4977 deletion (p=0.026).
Attendees, including hundreds of health professionals, gained access to the latest knowledge and developments in the field, from exclusive insights from one of the foremost authorities on atherosclerosis, Dr. Peter Libby, to innovations like new therapeutic agents and exciting advancements in renal protection. In the U.S.,
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content